Currently, the combination of dabrafenib and trametinib has been approved in China for three indications: the treatment of BRAF-V600-mutation-positive metastatic NSCLC, adjuvant treatment after surgery for BRAF-V600-mutation-positive melanoma, and the treatment of unresectable or metastatic melanoma. Here, BRAF is linked to metastatic melanoma.